KOLINPHARMA undertakes to operate ethically and asks and expects from its
I) employees and collaborators,
II) consultants, collaborators, temporary workers and freelancers,
III) third party partners such as contractors, suppliers, wholesale customers, ..., as well as
IV) members of corporate bodies,

behavior aligned with:

• Group Code of Ethics and KOLINPHARMA Group Values;
• Organization, management and control model pursuant to Legislative Decree 231 of 8 June 2001;
• Anti-corruption policy

The normative source is the law 30 November 2017, n.179 which integrated art.6 of Legislative Decree 231/2001, providing for the institution of whistleblowing also in the private sector, introduced into the public sector by art.1, paragraph 51, of law 190/2012.

Reporting (so-called whistleblowing) is an act of manifestation of civic sense, through which the whistleblower contributes to the emersion of illegal behavior. The company's Board of Directors has approved the whistleblowing procedure, a procedure for managing the reporting of offenses, in February 2019, ensuring confidentiality and anonymity in the event of reporting of offenses.

The recipient of the report is the company's Supervisory Body (hereinafter also the "SB") appointed by the Company pursuant to art. 6 of Legislative Decree 231/01

April 2024